New program tracks rare side effect of schizophrenia shot
NCT ID NCT01088386
First seen Feb 01, 2026 · Last updated Jun 12, 2026 · Updated 18 times
Summary
This program watches patients who get Zyprexa Relprevv, a long-acting shot for schizophrenia, to lower the chance of a rare side effect called post-injection delirium/sedation syndrome (PDSS). Up to 4,000 people will be followed to track how often PDSS happens and what might cause it. The goal is to make the medicine safer for everyone who uses it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
United BioSource Corporation
Blue Bell, Pennsylvania, 19422, United States
Conditions
Explore the condition pages connected to this study.